PL1713503T3 - Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby - Google Patents

Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby

Info

Publication number
PL1713503T3
PL1713503T3 PL05722948T PL05722948T PL1713503T3 PL 1713503 T3 PL1713503 T3 PL 1713503T3 PL 05722948 T PL05722948 T PL 05722948T PL 05722948 T PL05722948 T PL 05722948T PL 1713503 T3 PL1713503 T3 PL 1713503T3
Authority
PL
Poland
Prior art keywords
inhibition
factor
complement pathway
methods related
alternative complement
Prior art date
Application number
PL05722948T
Other languages
English (en)
Inventor
Vernon Michael Holers
Joshua M Thurman
Christian Taube
Erwin W Gelfand
Gary Steven Gilkeson
Original Assignee
Univ Colorado Regents
Nat Jewish Health
Musc Found For Res Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/015040 external-priority patent/WO2004103288A2/en
Application filed by Univ Colorado Regents, Nat Jewish Health, Musc Found For Res Dev filed Critical Univ Colorado Regents
Publication of PL1713503T3 publication Critical patent/PL1713503T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL05722948T 2004-02-10 2005-02-10 Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby PL1713503T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54359404P 2004-02-10 2004-02-10
PCT/US2004/015040 WO2004103288A2 (en) 2003-05-13 2004-05-13 Method of preventing recurrent miscarriages
US63623904P 2004-12-14 2004-12-14
EP05722948.6A EP1713503B1 (en) 2004-02-10 2005-02-10 Inhibition of factor b, the alternative complement pathway and methods related thereto
PCT/US2005/004346 WO2005077417A1 (en) 2004-02-10 2005-02-10 Inhibition of factor b, the alternative complement pathway and methods related thereto

Publications (1)

Publication Number Publication Date
PL1713503T3 true PL1713503T3 (pl) 2014-02-28

Family

ID=34865159

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05722948T PL1713503T3 (pl) 2004-02-10 2005-02-10 Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby

Country Status (5)

Country Link
EP (2) EP1713503B1 (pl)
AU (1) AU2005212369B2 (pl)
CA (1) CA2561531C (pl)
PL (1) PL1713503T3 (pl)
WO (1) WO2005077417A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
WO2006128006A1 (en) 2005-05-26 2006-11-30 The Regents Of The University Of Colorado Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US7759304B2 (en) 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
EP2073898A1 (en) 2006-10-10 2009-07-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement inhibition for improved nerve regeneration
CN101668773B (zh) * 2007-03-14 2016-08-31 亚力史制药公司 人工程化抗b因子抗体
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
BR112012029067A2 (pt) 2010-05-14 2019-09-24 Univ Colorado Regents grupos-alvo de receptor do complemento 2 (cr2) melhorados.
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
PT2661433T (pt) 2011-01-04 2017-10-24 Novartis Ag Compostos de indole ou seus análogos úteis para o tratamento da degeneração macular relacionada com a idade (amd)
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
EP2867225B1 (en) 2012-06-28 2017-08-09 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
ES2644700T3 (es) 2012-06-28 2017-11-30 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
US9815819B2 (en) 2012-06-28 2017-11-14 Novartis Ag Complement pathway modulators and uses thereof
WO2014002058A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
CA2882724A1 (en) 2012-07-12 2014-01-16 Novartis Ag Complement pathway modulators and uses thereof
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
ES2514165B1 (es) * 2013-03-27 2015-09-09 Consejo Superior De Investigaciones Científicas (Csic) Anticuerpo anti-factor b, composición farmacéutica útil para el tratamiento de enfermedades del complemento y sus aplicaciones
EA036496B1 (ru) 2014-05-01 2020-11-17 Ионис Фармасьютикалз, Инк. Конъюгированные олигонуклеотиды для модулирования экспрессии фактора комплемента b
EP3452510A4 (en) 2016-04-04 2020-01-15 Bioverativ USA Inc. ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF
JP7369121B2 (ja) * 2017-10-11 2023-10-25 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体活性を誘発する方法
EP4139350A4 (en) 2020-04-20 2024-04-24 Genzyme Corporation Humanized anti-complement factor bb antibodies and uses thereof
CN121320460B (zh) * 2025-12-16 2026-04-17 山东第二医科大学 构建小鼠肥胖模型的方法及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2043472A1 (en) 1990-06-04 1991-12-05 Mitsutaka Miyabayashi Electrode for secondary battery
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
AU1705100A (en) * 1998-10-09 2000-05-01 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
GB9930659D0 (en) 1999-12-24 2000-02-16 Bio Discovery Ltd Inhibitors of complement activation
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
US20040015040A1 (en) 2002-07-18 2004-01-22 The University Of Cincinnati Flexible, torsionable cardiac framework for heart wall actuation of the natural heart
JP4601426B2 (ja) 2002-09-06 2010-12-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体成分ｃ５に対する抗体を使用する喘息の処置の方法
US20070123466A1 (en) * 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages

Also Published As

Publication number Publication date
EP1713503A4 (en) 2008-08-06
EP1713503B1 (en) 2013-07-31
WO2005077417A1 (en) 2005-08-25
EP1713503A1 (en) 2006-10-25
CA2561531C (en) 2017-05-02
CA2561531A1 (en) 2005-08-25
EP2340850A1 (en) 2011-07-06
AU2005212369B2 (en) 2011-06-23
AU2005212369A1 (en) 2005-08-25
EP2340850A9 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
PL1713503T3 (pl) Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby
MX286273B (es) Composiciones y metodos para inhibicion de la via jak.
DK1713503T3 (da) Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
ZA200700351B (en) Compounds, compositions and methods
SG156674A1 (en) Asphaltene inhibition
EP1796489A4 (en) PROTECTIVE SHOES AND METHOD FOR PRODUCING THE SAME
IL178888A0 (en) Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives
PT1814555E (pt) S-mirtazapina para o tratamento de afrontamentos
EP1789055A4 (en) INHIBITORS OF THIAZOLOPYRIDINE KINASE
SI1713503T1 (sl) Inhibicija faktorja B, alternativna komplementa pot in relevantni postopki
GB2418628B (en) Improved laminates and the manufacture thereof
GB0414760D0 (en) The alternative
GB2421540B (en) Padlock
GB0514024D0 (en) Padlock
IL177759A0 (en) Cospeptin, cosmedin and their uses
GB0400537D0 (en) Le beanock/the beanock
GB2420465B (en) The smelly-vision
GB2414745C (en) Euroblock - flood prevention specification
GB0419656D0 (en) The bugcap
GB0406179D0 (en) The portaset
GB0417973D0 (en) The cat-stand
GB0400520D0 (en) The nano-disc
GB0412512D0 (en) The binhide
GB0424699D0 (en) The cool-spoon
GB0424686D0 (en) The speedshaft